Moberg Pharma Ab · OMXSTO:MOB

Moberg Pharma Ab — Investor Presentation (January 2015)

34 slides from Moberg Pharma Ab's investor presentation, Jan 18, 2015

  1. Slide 1: Moberg Pharma AB

    Moberg Pharma AB Providing Unique Products in Underserved Niches through Commercial and Innovation Excellence Investor presentation, January 18, 2015 Peter Wolpert, CEO & Founder 0

  2. Slide 2: Disclaimer

    Disclaimer Statements included herein that are not historical facts are forward-looking statements. Such forward- looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Moberg Pharma’s results could

  3. Slide 3: 2014 TV commercial in the Nordics

    2014 TV commercial in the Nordics 2 2

  4. Slide 4: Moberg Pharma: Providing Unique Products in Underserved Niches

    Moberg Pharma PROVIDING UNIQUE PRODUCTS IN UNDERSERVED NICHES Vision Strategic elements  Build a leading niche player in  Growth strategy strategic focus areas, such as: - Organic growth - Topical Foot Care/Dermatology - M&A/Innovation engine - Topical Pain Management - Additional areas to be adde

  5. Slide 5: Moberg Pharma

    Moberg Pharma PROVIDING UNIQUE PRODUCTS IN UNDERSERVED NICHES  Net Sales grew to 185 MSEK ($25m, TTM) - U.S. OTC Sales operations - Products sold in 40+ countries - 30 employees in Stockholm and NJ  Focus in OTC/Dermatology/Topicals - Leading U.S. OTC SKU in Nail Fungus - Superior PII data for MOB

  6. Slide 6: 18 consecutive quarters of Sales growth

    18 consecutive quarters of Sales growth Product Sales, TTM, MSEK 200 180 160 140 120 MSEK 100 80 60 40 20 0 Q110 Q210 Q310 Q410 Q111 Q211 Q311 Q411 Q112 Q212 Q312 Q412 Q113 Q213 Q313 Q413 Q114 Q214 Q314 5 5

  7. Slide 7: Rapid growth in Net Sales and EBITDA

    Rapid growth in Net Sales and EBITDA Jan – Sep 2013 Jan - Sep 2014 Net Sales, MSEK EBITDA, MSEK EBITDA Commercial Operations, MSEK 156 (+29%) 121 Neg 14% 9% 22% 34 (+240%) 22 10 -10 NOTE: Commercial EBITDA does not include R&D and Business Development expenses 6 for future products outside existing

  8. Slide 8: Strong Q3 - 35% sales growth, US main driver

    Launch of Emtrix® in Malaysia Strong Q3  35% sales growth – US main driver – North America grew by 40% - Organic growth and contributions from acquired brands. Rapid growth and >50% market share (OTC) in Canada – European sales grew 7% – SE Asia launch kicked off with Emtrix® in Malaysia  Excellen

  9. Slide 9: Majority of revenue from direct OTC sales, RoW growth starting to pick up

    Majority of revenue from direct OTC sales, RoW growth starting to pick up Distribution of revenue, Jan – September 2014 JointFlex Other RoW Sales via 14% 13% 7% distributors 29% Europe Kerasal 18% 15% Nalox/ Direct OTC Kerasal Nail Americas Sales 71% 58% 75% Channels Products Geography 8 8

  10. Slide 10: Commercial Operations & Innovation Engine

    Commercial Operations & Innovation Engine

  11. Slide 11: No 1. SKU in the U.S.

    U.S. retail sales of Kerasal Nail increased 31% in Q314 Kerasal Nail™ – U.S. market share1) No 1. SKU in the U.S.  From 0  23% market share in 3 years  Available at all major retailers >30 000 stores  On Top-50 list of ”Most Innovative New Products” - Drug Store News, 2012  Three clinical studi

  12. Slide 12: Efficient infrastructure for building OTC brands in the U.S.

    Efficient infrastructure for building OTC brands in the U.S. CMOs Sales Force Retailers/Wholesalers Sales and marketing/Brand Management Logistics Emerson Healthcare 11 11

  13. Slide 13: Outperforming the market through combining Brand and IP equity

    ® Outperforming the market through combining Brand and IP equity Organic growth YTD (Value), % Strategic brands • Kerasal® - Foot care Emtrix® 17% • Domeboro® - Derma/Skin irritation Mature brands 5% • Jointflex® - Ext. analgesic • Vanquish® - Int. analgesic Moberg U.S. U.S. OTC market • Fergon® - I

  14. Slide 14: Distributor Sales well positioned for further growth

    Distributor Sales well positioned for further growth Nalox™/Kerasal Nail®  Sales in >40 markets  Stronger claims recently approved  Potential for further growth  Strong sales in Canada as response to launch of consumer advertising,  Market leader with >50% of OTC sales (value) and 30% of all Rx

  15. Slide 15: Asian launch initiated in Malaysia under our Emtrix brand

    Asian launch initiated in Malaysia under our Emtrix® brand 14 14

  16. Slide 16: 2014 H2 TV commercial in Malaysia

    2014 H2 TV commercial in Malaysia 15 15

  17. Slide 17: Distribution in >1000 pharmacies in Malaysia (97%)

    Distribution in >1000 pharmacies in Malaysia (97%) 16 16

  18. Slide 18: Counter Top

    17 Counter Top [E| EMTRIX™ Fi =i > ss | i is

  19. Slide 19: Window stickers in pharmacy

    Window stickers in pharmacy 18 18

  20. Slide 20: Pharmacy training

    Pharmacy training 19 19

  21. Slide 21: Pipeline assets in phase II

    Pipeline assets in phase II - Building on Topical drug delivery know how and IP portfolio Peak sales Pipeline Indication Status potential, m$ USP asset MOB-015 Onychomycosis Phase II 250-500 Topical terbinafine with fast completed visible improvement and superior cure rates BUPI Oral Mucositis Phase

  22. Slide 22: MOB-015 Excellent Phase II results

    MOB-015 Excellent Phase II results 54% Study design  Open label, n=25, 24 patients completed  Once daily for 48w Last follow-up at 60w MYCOLOGICAL CURE AT 15  Severely affected nails, MONTHS* 60% mean nail involvement 29% MYCOLOGICAL CURE AND EXCELLENT CLINICAL IMPROVEMENT OR CURE** Well tolerate

  23. Slide 23: Phase II results indicate MOB015 has potential to become best in class

    Phase II results indicate that MOB015 has potential to become best in class (topical drug for Onychomycosis) Mycological cure Active Product Company Form at 6 months at 12/15 Comment months Terbinafine MOB-015 Moberg Pharma Topical 40%1) 54% 25-75% affected* Efinaconazole Jublia Valeant Topical - 54

  24. Slide 24: Rationale for the superiority of MOB-015

    Rationale for the superiority of MOB-015  54% mycological cure, in patients with severe onychomycosis (60% mean involvement)  Excellent clinical improvement, full photo documentation  High terbinafine levels in patients: - In nail bed: 45 µg/g (median value) 40x Oral TBF - In nail: 1610 µg/g (med

  25. Slide 25: MOB-015 vs Jublia - Target Product Profile for mild-moderate affected nails

    CONFIDENTIAL MOB-015 vs Jublia – Target Product Profile for mild-moderate affected nails Mycological cure Complete Almost Clear nail % of patients cure cured or growth experiencing visual cured improvement after 1 month Product at 6 at 12/15 at 12/15 at 12/15 at 12/15 at 1 month months months months

  26. Slide 26: Example of successful treatment with MOB-015

    Example of successful treatment with MOB-015 Before After 25 25

  27. Slide 27: Example of successful treatment with MOB-015

    Example of successful treatment with MOB-015 Before After 26 26

  28. Slide 28: Example of successful treatment with MOB-015

    Example of successful treatment with MOB-015 Before After 27 27

  29. Slide 29: MOB-015 - Next steps

    MOB-015 – Next steps  Dual track – Discussion with industrial/financial partners ongoing  Refine Ph III program and CMC preparations 28 28

  30. Slide 30: BUPI - Long-acting lozenge with bupivacaine

    BUPI – Long-acting lozenge with bupivacaine - Phase II started Oct 2014 Product & Indication  Bupivacaine lozenge for oral pain relief (mouth and throat)  1st indication: Oral Mucositis in cancer patients. Large unmet need  Other indications: Burning Mouth Syndrome, Sjögren’s syndrome, Upper gast

  31. Slide 31: Team

    Team

  32. Slide 32: Management and Board with strong track record

    Management and Board with strong track record Management experience Board experience McKinsey, AZ, Q-Med, Biogen Idec, Pharmacia/Pfizer, Lundbeck, Genmab, Quintiles, J&J, Insight, Pfizer Barrier Therapeutics, NCH Peter Wolpert Martin Ingman Jeff Vernimb Mats Pettersson Wenche Rolfsen Geert Cauwenber

  33. Slide 33: Increasing high quality institutional investors (SW, US, FR)

    Increasing high quality institutional investors (SW, US, FR) Shareholders No of shares Capital and votes, % ÖSTERSJÖSTIFTELSEN 2 245 179 16,1 HANDELSBANKEN FONDER 834 477 6,0 JPM CHASE NA (Altaris Capital Partners) 825 652 5,9 FÖRSÄKRINGSAKTIEBOLAGET, AVANZA PENSION 798 417 5,7 GRANDEUR PEAK 720 680

  34. Slide 34: Focus next 12 months

    Focus next 12 months PROVIDING UNIQUE PRODUCTS IN UNDERSERVED NICHES  Drive growth and EBITDA improvements  Fuel strong U.S growth - K-Nail and Neurocream launch - Line extensions and new SKUs  Grow Distributor Sales - EU: Extended indication - Launches in China/SE Asia, Mena  BD/Innovation Engi

Moberg Pharma — Investor Presentation (January 2015) on 6ix